171 related articles for article (PubMed ID: 38373988)
1. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Yassin-Kassab A; Chatterjee S; Khan N; Wang N; Sandulache VC; Huang EH; Burns TF; Duvvuri U
BMC Cancer; 2024 Feb; 24(1):233. PubMed ID: 38373988
[TBL] [Abstract][Full Text] [Related]
2. Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.
Vyas A; Duvvuri U; Kiselyov K
Biochem J; 2019 Dec; 476(24):3705-3719. PubMed ID: 31790150
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
[TBL] [Abstract][Full Text] [Related]
4. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.
Godse NR; Khan N; Yochum ZA; Gomez-Casal R; Kemp C; Shiwarski DJ; Seethala RS; Kulich S; Seshadri M; Burns TF; Duvvuri U
Clin Cancer Res; 2017 Dec; 23(23):7324-7332. PubMed ID: 28899969
[No Abstract] [Full Text] [Related]
5. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.
Tong T; Qin X; Jiang Y; Guo H; Wang X; Li Y; Xie F; Lu H; Zhai P; Ma H; Zhang J
BMC Med; 2022 Jul; 20(1):231. PubMed ID: 35773668
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.
Vyas A; Gomez-Casal R; Cruz-Rangel S; Villanueva H; Sikora AG; Rajagopalan P; Basu D; Pacheco J; Hammond GRV; Kiselyov K; Duvvuri U
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2100670119. PubMed ID: 35286200
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
8. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5.
Jiang Y; Guo H; Tong T; Xie F; Qin X; Wang X; Chen W; Zhang J
Mol Ther; 2022 Jan; 30(1):448-467. PubMed ID: 34111560
[TBL] [Abstract][Full Text] [Related]
9. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism.
Jones TM; Espitia CM; Ooi A; Bauman JE; Carew JS; Nawrocki ST
Cell Death Dis; 2022 Apr; 13(4):350. PubMed ID: 35428778
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
[TBL] [Abstract][Full Text] [Related]
11. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
[TBL] [Abstract][Full Text] [Related]
12. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
13. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
15. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
18. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
19. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
20. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
